Effects of serotonin on platelet activation in whole blood

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 8, 1997, Pages 517-523

  Li, N ^a   Wallen N H ^a   Ladjevardi, M ^a   Hjemdahl, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ADP; Filtragometry; Flow cytometry; Impedance aggregometry; Platelet activation; Serotonin; Thrombin

Indexed keywords

ADENOSINE DIPHOSPHATE; SEROTONIN; SEROTONIN 2A RECEPTOR; THROMBIN;

ARTICLE; BLOOD; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMPEDANCE; MALE; MICROFILTRATION; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 0031437035     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199711000-00006     Document Type: Article

References (32)

1. White JG. A biphasic response of platelets to serotonin. Scand J Haematol 1970; 7: 145-151.
2. De Clerck FF, David JL, Janssen PAJ. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2 receptor antagonist. Agents Actions 1982; 12: 388-397.
3. De Clerck F, Xhonneux B, De Chaffoy de Courcelles D. Functional expression of the amplification reaction between serotonin and epinephrine on platelets. J Cardiovasc Pharmacol 1988; 11 (suppl 1): S1-S5.
4. Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993; 53: 209-215.
5. Malmgren R. The potentiating effect of serotonin and epinephrine on collagen-induced whole blood aggregation and secretion. Platelets 1990; 1: 213-215.
6. Bevan J, Heptinstall S. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. Thromb Res 1985; 38: 189-194.
7. Bevan J, Heptinstall S. Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation. Naunyn-Schmiedebcrg's Arch Pharmaml 1986; 334: 341-345.
8. Krolll MH, Helums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996; 88: 1525-1541.
9. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, et al. The role of von Willebrand factor and fibrmogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240.
10. Zeller JA, Dayhoff RE, Eurcnius K, Russell W, Ledley RS. Aldehyde-induced platelet aggregation. Clin Lab Haemat 1984; 6: 145-155.
11. Beck O, Wallén NH, Bröijersén A, Larsson PT, Hjemdahl P. On the accurate determination of serotonin in human plasma. Biochem Biophys Res Commun 1993; 196: 260-266.
12. Söderbäck U, Sollevi A, Wallén NH, Larsson PT, Hjemdahl P. Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as asssessed by filtragometry. Clin Sci 1991; 81: 691-694.
13. Larsson PT, Wallén NH, Martinsson A, Egberg N, Hjemdahl P. Significance of platelet beta-adrenoceptors for platelet responses in vivo and in vitro. Thromb Haemost 1992; 68: 687-693.
14. Herbert JM, Bernat A, Barthelemy G, Dol F, Rinaldi M. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist. Thromb Haemost 1993; 69: 262-267.
15. Herbert JM, Bernat A, Sainte MM, Dol F, Rinaldi M. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 1993; 69: 268-271.
16. Goodall AH. Platelet activation during preparation and storage of concentrates: detection by flow cytometry. Blood Coag Fibrinol 1991; 2: 377-382.
17. Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol & Biol Psychiat 1982; 6: 277-295.
18. Beving H, Bjerkenstedt L, Malmgren R, Olsson P, Unge G. The effects of citalopram (Lu 10-171) on the serotonin (5-HT) uptake kinetics in platelets from endogenously depressed patients. J Neural Transm 1985; 61: 95-104.
19. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-666.
20. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coag Fibrinol 1994; 5: 121-131.
21. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315.
22. Hornstra G, ten Hoor F. The filtragometer: a new device for measuring platelet aggregation in venous blood of man. Thromb Diath Haemorrh 1975; 34: 531-544.
23. Hjemdahl P, Larsson PT, Wallén NH. Effects of stress and β-blockade on platelet function. Circulation 1991; 84 (suppl VI): VI-44-VI-61.
24. Lanza F, Beretz A, Stierle A, Hanau, D., Kubina M, Cazenave J-P. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-H1288.
25. Fenton II JW. Regulation of thrombin generation and functions. Semin Thromb Hemost 1988; 14: 234-240.
26. Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1989; 78: 701-711.
27. Ashton JH, Golino P, McNatt JM, Buja LM, Willerson JT. Serotonin S2 receptor blockade (LY53857) combined with thromboxane A2/prostaglandin H2 receptor blockade (SQ29,548) provide protection against epinephrine-induced intermittent thrombosis in severely narrow canine coronary arteries. J Am Coll Cardiol 1989; 13: 755-763.
28. Brune S, Tebbe U, Schmidt T, Benn HP, Seiler KU, Kreuzer H. Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin. Clin Physiol Biochem 1990; 8(Suppl 3): 81-84.
29. Noble MI, Drake HA. Evidence for a role of serotonin in initiation of coronary arterial thrombosis in dog and man. Clin Physiol Biochem 1990; 8(Suppl 3): 50-55.
30. Klein W, Eber B, Dusleag J, Rotman B, Koltringer P, Luha O, et al. Ketanserin prevents early restenosis following percutaneous transluminal coronary angioplasty. Clin Physiol Biochem 1990; 8(Suppl 3): 101-107.
31. De Clerck F, Xhonneux B, Leysen J, Janssen PAJ. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 8: 2807-2811.
32. Gershon MD, Tamir H. Peripheral sources of serotonin and serotonm-binding proteins. In: Vanhoutte PM, ed. Serotonin and the Cardiovascular System. New York, Raven Press, 1985; 15-26.